{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0048","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"PFS at 12 months is a dichotomized outcome indicating whether or not a participant was progression free (and alive) at 12 months from the date of randomization.","groups":[{"description":"Thalidomide (Thal) + Zolendronic acid (ZLD)","id":"OG000","title":"Arm I: Thal/ZLD"},{"description":"Zoledronic acid (ZLD)","id":"OG001","title":"Arm II: ZLD"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 months","title":"12-month Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"participants"}